COPENHAGEN, Sept 13 (Reuters) - Danish drugmaker Novo Nordisk said new data showed people with type 2 diabetes experienced improvements in controlling blood sugar levels when using its diabetes drug ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...

Novo Nordisk has posted another healthy set of figures for the first nine months of the year this morning, helped by a good start for its new diabetes drug Victoza. Novo Nordisk has posted another ...

Sorry, Victoza. Novo Nordisk ($NVO) has given up on the GLP-1 drug as a treatment for Type 1 diabetes, at least for now. A blockbuster in the Type 2 form of the ...

LONDON (Reuters) - Novo Nordisk's big new drug hope Victoza has been recommended for limited use on Britain's state-run health service as a treatment for diabetes, the Danish drugmaker said on Monday.

Danish drugmaker Novo Nordisk will be celebrating news that Victoza has been recommended as a treatment for diabetes type 2 for National Health Service patients in England and Wales. Danish drugmaker ...

This week there was news from a small study that showed that Novo Nordisk’s Victoza could serve as a viable treatment for type 1 diabetes, as a supplement to insulin. People with type 1 diabetes can ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.

A woman who’s been on a drug similar to Ozempic for nearly a decade is sharing what she’s learned. Danielle Payton, 33, is believed to be one of the longest-serving patients on a GLP-1 injection. The ...

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay to use ...